Exploring new guidances and future challenges for pharma trading partners in meeting looming DSCSA mandates in the US
Martha M. Rumore, Frier Levitt, LLC
Advertisement
Articles by Martha M. Rumore, Frier Levitt, LLC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Mark Cuban Confirms Cost Plus Drugs Partnership
2
Why Rising Complexity and R&D Costs Are Fueling Specialty Drug Spending
3
Pharma Pulse: MJH Life Sciences Expands into Health Systems, Novo Nordisk Board Shakeup Moves Markets, and Mark Cuban Grows Cost Plus Drugs Network
4
BioNTech Launches Public Exchange Offer for CureVac in $1.25B All-Stock Deal
5
